Promontory Therapeutics is at the forefront of oncology, developing cutting-edge small molecule immunogenic anti-cancer agents. Their lead agent, PT-112, is a highly potent inducer of immunogenic cell death (ICD), currently undergoing Phase 2 clinical development. What sets Promontory apart is their unique mechanism of action, demonstrated single-agent activity, and established safety profile, along with its synergy with immune checkpoint inhibitors.

Their dedication to advancing small molecule immunotherapy is driven by a commitment to solving previously unsolved problems and addressing unmet needs in cancer treatment. By inducing an adaptive immune response, PT-112 offers great promise as a clinical drug candidate. Stay up to date with their latest news and updates, such as the expansion of the Phase 2 trial in Metastatic Castrate-Resistant Prostate Cancer and the National Cancer Institute Phase 2 Clinical Trial in Thymoma and Thymic Carcinoma.

For more information, contact Promontory Therapeutics at their New York headquarters